Market Place
Sourcing Support
TME Pharma Receives €2.4M Grant for NOX-A12 Brain Cancer Trial
31 Oct 2024 //
BUSINESSWIRE
TME Pharma Plans To Externalize And Monetize NOX-E36 Asset
22 Jul 2024 //
BUSINESSWIRE
NOX-A12 Plus Bevacizumab & Radiotherapy Shows Sustained Survival in Glioblastoma
29 Jun 2023 //
ONCLIVE
NOXXON Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication
05 Jan 2022 //
BUSINESSWIRE
NOXXON Provides Update on Timing for Upcoming Trials of NOX-A12
03 Nov 2021 //
BUSINESSWIRE
NOXXON Reports H1 2021 Financial Results and Provides Business Update
22 Oct 2021 //
BUSINESSWIRE
NOXXON Enrolls Last Patient in Phase 1/2 GLORIA Study in brain cancer
22 Sep 2021 //
BUSINESSWIRE
NOXXON to Attend the German Fall Conference on September 6 & 7, 2021
25 Aug 2021 //
BUSINESSWIRE
NOXXON UPDATE TO THE CLINICAL PROGRAMS FOR NOX-A12
05 Aug 2021 //
BUSINESSWIRE
NOXXON UPDATES ON CURRENT CLINICAL PROGRAMS ASSESSING NOX-A12 IN BRAIN
05 Aug 2021 //
BUSINESSWIRE
NOXXON Announces Data Safety Monitoring Board Validates NOX-A12
10 May 2021 //
BUSINESSWIRE
NOXXON Announces Data Safety Monitoring Board Validates NOX-A12 Highest
10 May 2021 //
BUSINESSWIRE
NOXXON Announces €1.2M Equity Raise Through Conversion of Warrants
30 Apr 2021 //
BUSINESSWIRE
Noxxon Pharma secures DSMB approval to continue brain cancer study
15 Mar 2021 //
CLINICALTRIALSARENA
NOXXON Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies
30 Dec 2020 //
BUSINESSWIRE
NOXXON Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies
29 Dec 2020 //
BUSINESSWIRE
NOXXON Announces That Data Safety Monitoring Board Validates Further NOX-A12
09 Nov 2020 //
BUSINESSWIRE
NOXXON Publishes Interim 2020 Results
30 Oct 2020 //
BUSINESSWIRE
NOXXON Announces 3 Additional Clinical Centers to Recruit Patients for NOX-A12
20 Oct 2020 //
BUSINESSWIRE
NOXXON ERWEITERT VOLUMEN UND VERBESSERT BEDINGUNGEN FÜR
14 Oct 2020 //
BUSINESSWIRE
NOXXON Presents Final Data From Phase 1/2 NOX-A12 / Keytruda Combination Trial
16 Sep 2020 //
BUSINESSWIRE
NOXXON to Present Final Clinical Data From the NOX-A12 / Keytruda®
12 Aug 2020 //
BUSINESSWIRE
NOXXON Announces First Brain Cancer Patient From Second Dose Cohort 4 Weeks
27 Jul 2020 //
BUSINESSWIRE
NOXXON Enrolls First Patient in the Second Dose Cohort of Trial NOX-A12
30 Jun 2020 //
BUSINESSWIRE
Noxxon Announces Issuance of Convertible Bonds Under Agreement With Atlas
12 Jun 2020 //
BUSINESSWIRE
NOXXON Announces Capital Increase of € 5.5 M by Private Placement
08 May 2020 //
BUSINESSWIRE
NOXXON to Present Latest Clinical Data From the NOX-A12 / Keytruda®
14 Apr 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.